Tyrosine

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: focus mood energy

Research Overview

Across the studies reviewed here, tyrosine research is most heavily concentrated on signaling mediated by tyrosine phosphorylation and its therapeutic exploitation, particularly in oncology. The most studied areas include receptor and non-receptor tyrosine kinases as drug targets (e.g., EGFR and ALK in non-small cell lung cancer; KIT and PDGFRA in gastrointestinal stromal tumor), the clinical use of tyrosine kinase inhibitors (TKIs) and their sequencing in hepatocellular carcinoma (HCC), and the broader regulatory biology of protein tyrosine phosphatases (PTPs) that counterbalance kinase activity. Additional focused areas include immune signaling nodes that depend on tyrosine phosphorylation status (e.g., ISGF3 in type I interferon responses) and kinase families implicated in age-related disease biology (e.g., DYRK1A), as well as human genetics clarifying the functional consequences of variants in tyrosine kinase 2 (TYK2) relevant to autoimmunity.

The strongest evidence supports tyrosine phosphorylation as a central, disease-relevant control system and validates tyrosine-directed therapeutics in defined molecular contexts. Clinically, robust benefit from TKIs is best established where tumors are driven by actionable kinase alterations: EGFR- and ALK-driven NSCLC and KIT/PDGFRA-mutant GIST, where mutation-informed treatment selection is integral to management. In HCC, TKIs remain important, but the most practice-changing survival gains in first line have come from immunotherapy combinations (e.g., anti–PD-L1 plus anti-VEGF; anti–PD-L1 plus anti–CTLA-4), while ICI–TKI combinations have shown inconsistent phase III overall survival results. Mechanistically, the studies also support that tyrosine phosphorylation state can qualitatively shift signaling outputs (e.g., phosphorylated vs unphosphorylated ISGF3 in interferon biology) and that PTPs are regulated, specific signaling modulators rather than merely constitutive “housekeeping” enzymes.

Key gaps include improved predictive biomarkers and treatment sequencing strategies, especially in HCC where liver function, cirrhosis, and hepatic decompensation complicate therapeutic choice and trial endpoints. Resistance biology remains a major unmet need: in GIST, heterogeneous secondary KIT/PDGFRA mutations limit later-line efficacy and motivate mutation-specific inhibitor development; in immuno-oncology, intrinsic resistance to ICIs and tumor-intrinsic roles of PD-L1 and interferon signaling warrant deeper mechanistic and translational study. More research is also needed to translate regulatory insights about PTP control (e.g., redox modulation, allostery, oligomerization) into tractable therapeutics, to refine TYK2-targeting strategies that balance protection from autoimmunity against immunodeficiency risk, and to clarify the therapeutic potential and safety of targeting DYRK1A and related kinases in age-associated diseases.

1. What conditions has Tyrosine been studied for?

  • Not directly studied as a dietary supplement in these studies. The studies reviewed here focus on tyrosine-related biology (tyrosine phosphorylation) and tyrosine kinase–targeted drugs (tyrosine kinase inhibitors), rather than supplementation with the amino acid L-tyrosine.

  • Advanced hepatocellular carcinoma (HCC): Multiple studies discuss systemic therapy for HCC, including combinations of immune checkpoint inhibitors (ICIs) with tyrosine kinase inhibitors (TKIs) and anti-angiogenic agents, plus sequencing considerations in cirrhosis.

  • Non-small cell lung cancer (NSCLC): Several studies describe EGFR-mutated and ALK-rearranged NSCLC treated with targeted therapy using TKIs (including irreversible EGFR inhibitors such as osimertinib).

  • Gastrointestinal stromal tumor (GIST): Discussed as a model disease driven by activating mutations in receptor tyrosine kinases (KIT, PDGFRA) and treated with TKIs (e.g., imatinib and later-line agents).

  • Autoimmune diseases (genetics/target discovery): One abstract focuses on TYK2 (tyrosine kinase 2) genetic variants and their association with autoimmune disease risk, positioning TYK2 as a therapeutic target.

  • Age-related and other diseases (target discovery): One abstract reviews DYRK1A (dual-specificity tyrosine-regulated kinase 1A) as implicated in varied human diseases and as a potential therapeutic target.

  • Hereditary and other diseases involving protein tyrosine phosphatases (PTPs): Two studies review PTPs in hereditary disease and broader disease biology, emphasizing regulation of tyrosine phosphorylation signaling.

2. Does it work in treating those conditions? Summarize the evidence.

Important limitation: These studies do not provide evidence that L-tyrosine supplementation treats any condition. They provide evidence that therapies targeting tyrosine signaling (especially TKIs and immunotherapy combinations) can be effective in certain cancers, and that tyrosine-kinase–related genetics may inform therapeutic targeting in autoimmunity.

  • HCC: Single-agent ICIs show objective response rates around 15–20% and often without significant overall survival (OS) benefit; intrinsic resistance is noted in ~30% of HCC. Combination approaches have improved outcomes in some settings. The IMbrave150 trial is described as “practice-changing,” with atezolizumab + bevacizumab being the first regimen since sorafenib to demonstrate improved survival in the frontline setting. The HIMALAYA trial showed durvalumab + tremelimumab (STRIDE) superiority over sorafenib. In contrast, combinations of ICIs with TKIs have had inconsistent results, with only one phase III trial showing an OS benefit (per the review abstract).

  • NSCLC (precision oncology): For tumors with actionable drivers (notably EGFR mutations and ALK rearrangements), TKIs are described as improving outcomes compared with chemotherapy. Another abstract notes that for advanced EGFR-mutated NSCLC, EGFR-TKIs provide superior survival benefit over platinum chemotherapy, and that osimertinib showed superior survival benefit with a lower toxicity profile in a clinical trial (as summarized in the study).

  • GIST: The disease is largely driven by activating mutations in KIT or PDGFRA. First-line imatinib is described as achieving “remarkable prolonged disease control,” while subsequent lines provide more modest benefit. Treatment selection depends on mutation subtype.

  • Autoimmune disease (TYK2): The TYK2 abstract reports a protective homozygous genetic effect and proposes a “signaling optimum” between autoimmunity and immunodeficiency, supporting TYK2 as a potential drug target for certain autoimmune disorders. This is target validation evidence rather than evidence that tyrosine (the supplement) treats autoimmunity.

3. What health benefits does it have?

From these studies, no direct health benefits of L-tyrosine supplementation can be concluded. The benefits described relate to manipulating tyrosine-dependent signaling pathways with drugs or understanding tyrosine phosphorylation biology.

  • Therapeutic benefit via tyrosine kinase inhibition (drug class benefit, not supplement): TKIs are central to effective treatment in EGFR/ALK-driven NSCLC and KIT/PDGFRA-driven GIST, and remain important options in HCC (e.g., sorafenib, lenvatinib, regorafenib, cabozantinib discussed across HCC studies).

  • Improved outcomes via immunotherapy combinations in HCC: The studies highlight improved survival with atezolizumab-bevacizumab (IMbrave150) and durvalumab-tremelimumab (HIMALAYA/STRIDE), reflecting benefit from combining immune modulation with angiogenesis targeting or dual-checkpoint blockade.

  • Mechanistic insight that could enable new therapies: One abstract describes how tyrosine phosphorylation status of ISGF3 (phosphorylated vs unphosphorylated) shapes acute vs chronic type I interferon responses, and notes tumor-intrinsic roles of PD-L1 in modulating these responses—potentially informing future therapeutic strategies.

4. Does it have any downsides or side effects?

These studies do not report side effects of L-tyrosine supplementation. They do, however, imply clinically important downsides of tyrosine-pathway–targeting cancer therapies and of dysregulated tyrosine phosphorylation signaling.

  • HCC treatment tolerability and liver function constraints (therapy-related): One HCC review emphasizes that many patients will still receive TKIs due to contraindications to ICIs, and that maintaining optimal liver function is crucial because hepatic decompensation (which may not coincide with tumor progression) can force treatment discontinuation. This highlights a major real-world downside of systemic therapy in cirrhotic patients: toxicity and decompensation risk can limit benefit.

  • Biologic trade-offs in immune signaling (mechanism-related): The TYK2 abstract describes an “optimum” between autoimmunity and immunodeficiency, implying that shifting TYK2 signaling (e.g., with inhibitors) could reduce autoimmune risk but potentially increase susceptibility to immunodeficiency-related problems—though specific adverse outcomes are not detailed in the study.

  • General disease risk from disrupted tyrosine phosphorylation regulation: The PTP-focused studies emphasize that disruption of regulatory mechanisms controlling PTP activity can cause human diseases, underscoring that tyrosine phosphorylation networks are tightly regulated and that perturbations can have harmful consequences.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings about L-tyrosine supplementation are provided in these studies. The genetics discussed relate to tyrosine kinases as drug targets and to mutation-driven selection of targeted therapies.

  • TYK2 variants (autoimmunity risk modulation): A genetic meta-analysis and functional follow-up identified a protective homozygous effect in TYK2, suggesting a signaling balance between autoimmunity and immunodeficiency and supporting TYK2 as a therapeutic target for some autoimmune disorders. This is relevant to drug development and potential patient stratification, not to tyrosine supplementation.

  • EGFR mutations and ALK rearrangements (NSCLC): These actionable alterations predict benefit from EGFR- and ALK-targeted TKIs; one abstract also highlights improved outcomes with more potent/irreversible EGFR inhibitors (e.g., osimertinib) in EGFR-mutated disease.

  • KIT/PDGFRA mutations (GIST): Mutation subtype determination is required to guide management; approved therapies are TKIs targeting KIT/PDGFRA activation, and heterogeneity/secondary mutations influence response and resistance.

References

  1. How cancer cells make and respond to interferon-I.
    HyeonJoo Cheon, Yuxin Wang, Samantha M Wightman, Mark W Jackson, George R Stark (2023) - Trends in cancer
  2. Targeted therapy for lung cancer: Beyond EGFR and ALK.
    Mercedes Herrera-Juárez, Cristina Serrano-Gómez, Helena Bote-de-Cabo, Luis Paz-Ares (2023) - Cancer
  3. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
    Inga-Marie Schaefer, Ronald P DeMatteo, César Serrano (2022) - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
  4. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.
    Calliope A Dendrou, Adrian Cortes, Lydia Shipman, Hayley G Evans, Kathrine E Attfield, Luke Jostins, Thomas Barber, Gurman Kaur, Subita Balaram Kuttikkatte, Oliver A Leach, Christiane Desel, Soren L Faergeman, Jane Cheeseman, Matt J Neville, Stephen Sawcer, Alastair Compston, Adam R Johnson, Christine Everett, John I Bell, Fredrik Karpe, Mark Ultsch, Charles Eigenbrot, Gil McVean, Lars Fugger (2016) - Science translational medicine
  5. Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.
    Giuseppe Cabibbo, Alessio Aghemo, Quirino Lai, Mario Masarone, Sara Montagnese, Francesca Romana Ponziani (2022) - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  6. The Omnipresence of DYRK1A in Human Diseases.
    Estelle Deboever, Alessandra Fistrovich, Christopher Hulme, Travis Dunckley (2022) - International journal of molecular sciences
  7. Protein tyrosine phosphatases in health and disease.
    Wiljan J A J Hendriks, Ari Elson, Sheila Harroch, Rafael Pulido, Andrew Stoker, Jeroen den Hertog (2013) - The FEBS journal
  8. Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.
    Zhi-Hong Yu, Zhong-Yin Zhang (2018) - Chemical reviews
  9. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Saroja Bangaru, Jorge A Marrero, Amit G Singal (2020) - Alimentary pharmacology & therapeutics
  10. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    Nicolò Brandi, Matteo Renzulli (2023) - International journal of molecular sciences
  11. Use and abuse of dietary supplements in persons with diabetes.
    Bridget A Hannon, William D Fairfield, Bryan Adams, Theodore Kyle, Mason Crow, Diana M Thomas (2020) - Nutrition & diabetes
  12. Vanadium Compounds as PTP Inhibitors.
    Elsa Irving, Andrew W Stoker (2017) - Molecules (Basel, Switzerland)
  13. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.
    Ahmad Assi, Mohamad Farhat, Maria Catherine Rita Hachem, Ziad Zalaquett, Marven Aoun, Mohammad Daher, Amer Sebaaly, Hampig-Raphaël Kourie (2023) - Journal of bone oncology
  14. New drugs for multiple sclerosis: new treatment algorithms.
    Bruce A C Cree, Hans-Peter Hartung, Michael Barnett (2022) - Current opinion in neurology
  15. Approaching a therapeutic inflection point for FLT3-mutated AML.
    Alexander E Perl (2025) - Blood
  16. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
    Víctor Albarrán, María Luisa Villamayor, Jesús Chamorro, Diana Isabel Rosero, Javier Pozas, María San Román, Juan Carlos Calvo, Patricia Pérez de Aguado, Jaime Moreno, Patricia Guerrero, Carlos González, Coral García de Quevedo, Pablo Álvarez-Ballesteros, María Ángeles Vaz (2022) - International journal of molecular sciences
  17. Curcumin as tyrosine kinase inhibitor in cancer treatment.
    A Golonko, H Lewandowska, R Świsłocka, U T Jasińska, W Priebe, W Lewandowski (2019) - European journal of medicinal chemistry
  18. Behavioral and cognitive effects of tyrosine intake in healthy human adults.
    Adrian Hase, Sophie E Jung, Marije aan het Rot (2015) - Pharmacology, biochemistry, and behavior


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!